182 related articles for article (PubMed ID: 7609616)
21. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
22. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo.
Mihm MJ; Schanbacher BL; Wallace BL; Wallace LJ; Uretsky NJ; Bauer JA
J Neurosci; 2001 Jun; 21(11):RC149. PubMed ID: 11344255
[TBL] [Abstract][Full Text] [Related]
23. Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system.
Romero-Ramos M; Venero JL; Garcia-Rodriguez S; Ayala A; Machado A; Cano J
Free Radic Res; 2003 Sep; 37(9):1003-12. PubMed ID: 14670008
[TBL] [Abstract][Full Text] [Related]
24. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra.
Pasinetti GM; Lerner SP; Johnson SA; Morgan DG; Telford NA; Finch CE
Brain Res Mol Brain Res; 1989 May; 5(3):203-9. PubMed ID: 2566883
[TBL] [Abstract][Full Text] [Related]
25. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
Stott SRW; Barker RA
Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
[TBL] [Abstract][Full Text] [Related]
26. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
27. Regulation of neurotensin-containing neurons in the rat striatum and substantia nigra. Effects of unilateral nigral lesion with 6-hydroxydopamine on neurotensin content and its binding site density.
Masuo Y; Pélaprat D; Montagne MN; Scherman D; Rostène W
Brain Res; 1990 Mar; 510(2):203-10. PubMed ID: 1970504
[TBL] [Abstract][Full Text] [Related]
28. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
Georgievska B; Kirik D; Björklund A
Exp Neurol; 2002 Oct; 177(2):461-74. PubMed ID: 12429192
[TBL] [Abstract][Full Text] [Related]
29. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Fuxe K; Janson AM; Rosén L; Finnman UB; Tanganelli S; Morari M; Goldstein M; Agnati LF
Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
[TBL] [Abstract][Full Text] [Related]
30. Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra.
Smith JA; Leslie FM; Broide RS; Loughlin SE
Neuroscience; 1993 Aug; 55(4):935-51. PubMed ID: 8232904
[TBL] [Abstract][Full Text] [Related]
31. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway.
Numan S; Lundgren KH; Wright DE; Herman JP; Seroogy KB
Brain Res Mol Brain Res; 1995 Apr; 29(2):391-6. PubMed ID: 7609629
[TBL] [Abstract][Full Text] [Related]
32. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems.
Norton CS; Neal CR; Kumar S; Akil H; Watson SJ
J Comp Neurol; 2002 Mar; 444(4):358-68. PubMed ID: 11891648
[TBL] [Abstract][Full Text] [Related]
33. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.
Sauer H; Oertel WH
Neuroscience; 1994 Mar; 59(2):401-15. PubMed ID: 7516500
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
[TBL] [Abstract][Full Text] [Related]
35. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
36. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
Quesada A; Micevych PE
J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine hydroxylase as a target for deltamethrin in the nigrostriatal dopaminergic pathway.
Liu GP; Ma Q; Shi N
Biomed Environ Sci; 2006 Feb; 19(1):27-34. PubMed ID: 16673815
[TBL] [Abstract][Full Text] [Related]
38. Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
Chen XY; Li J; Qi WQ; Shen SH
Histol Histopathol; 2007 Oct; 22(10):1085-90. PubMed ID: 17616935
[TBL] [Abstract][Full Text] [Related]
39. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
